Evogene (EVGN) Company Report

Evogene is undergoing a strategic transition to establish itself as a leader in computational chemistry, focusing on generative AI (Campus AI) for small molecule design in the pharmaceutical and agriculture industries.
The company implemented an organizational change and cost reduction plan, which led to total operating expenses net of approximately $2.9 million in Q3 2025, a significant decrease from $6.6 million in the same period of 2024.
The sale of the majority of Lavie Bio's activities to ICL in July 2025, along with the sale of Microboost AI for Ag, generated an income of approximately $7.9 million in Q3 2025, contributing to a net income of approximately $5.2 million for the quarter, compared to a net loss of $8.2 million in Q3 2024.
As of September 30, 2025, the company's cash and short-term bank deposit balance was approximately $16 million. Revenues for the nine months ending September 30, 2025, were approximately $3.5 million, down from $4 million in the prior year.

Nov 20, 2025, 2:00 PM

Evogene Reports Q3 2025 Net Income Amid Strategic Shift and Asset Sales

EVGN

Earnings

New Projects/Investments

Layoffs

Evogene reported a net income of approximately $5.2 million for Q3 2025, a significant improvement from a net loss of $8.2 million in the same period last year, primarily due to income from discontinued operations and decreased operating expenses.
The company is undergoing a strategic transition to become a leader in computational chemistry, focusing on the generative design of small molecules for the pharmaceutical and agriculture industries, utilizing its Campus AI platform. This shift included a cost reduction plan, with Q3 2025 total operating expenses net of approximately $2.9 million, down from $6.6 million in Q3 2024.
As of September 30, 2025, Evogene's cash and short-term bank deposit balance was approximately $16 million, bolstered by the sale of Lavie Bio's assets and Microboost AI for Ag to ICL, which generated approximately $7.9 million in income during Q3 2025.
For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from $4 million in the same period last year, mainly due to lower revenue from AgPlenus activities, which included a one-time payment from Bayer during the first quarter of 2024.

Nov 20, 2025, 2:00 PM

Evogene Reports Q3 2025 Financial Results and Strategic Transition Progress

EVGN

Earnings

New Projects/Investments

M&A

Evogene reported a net income of approximately $5.2 million for the third quarter ended September 30, 2025, a significant improvement compared to a net loss of approximately $8.2 million in the same period last year, primarily driven by income from discontinued operations, net, of approximately $7.9 million from the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL.
Revenues for the third quarter of 2025 were approximately $0.3 million, a decrease compared to approximately $1.7 million in the same period of 2024, mainly due to reduced seed sales generated by Casterra and lower revenue from AgPlenus activities.
Total operating expenses, net, for the third quarter of 2025 decreased to approximately $2.9 million from approximately $6.6 million in the same period of 2024, reflecting the impact of an organizational realignment and cost-reduction plan.
As of September 30, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $16.0 million. The company is also advancing its strategic transition toward computational chemistry, focusing on the generative design of small molecules.

Nov 20, 2025, 12:00 PM

Evogene Reports H1 2025 Financials, Strategic Restructuring, and Divestitures

EVGN

Earnings

M&A

Layoffs

Evogene reported revenues of approximately $3.2 million for the six months ended June 30, 2025, an increase from $2.3 million in the prior year, while its overall loss decreased by 21.4% to approximately $7.7 million.
The company is undergoing a strategic shift, focusing on its ChemPass AI tech-engine, which includes integrating AgPlenus's activities into Evogene and implementing workforce reductions of 40% at AgPlenus and 30% at Evogene, with the full effect expected in the second half of 2025.
On July 8, 2025, Evogene completed the sale of most of Lavie Bio's activities and the MicroBoost AI Tech-Engine for agriculture to an ICL affiliate for a total consideration of approximately $18.714 million.
As of June 30, 2025, Evogene held approximately $11.9 million in cash and cash equivalents and short-term bank deposits, which management believes will be sufficient to meet projected cash requirements for at least the next 12 months.
A 1-for-10 reverse share split was effected after market close on July 24, 2024, retroactively adjusting all share and per share amounts presented.